华中科技大学学报（医学版）
華中科技大學學報（醫學版）
화중과기대학학보（의학판）
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
2015年
5期
524-527
,共4页
刘璐%游如旭%单风平%曾凡波%贺国芳
劉璐%遊如旭%單風平%曾凡波%賀國芳
류로%유여욱%단풍평%증범파%하국방
蛋氨酸脑啡肽%抑制肿瘤%减毒增效%免疫功能
蛋氨痠腦啡肽%抑製腫瘤%減毒增效%免疫功能
단안산뇌배태%억제종류%감독증효%면역공능
methionine-enkephalin(MEK)%anti-tumor%attenuating and synergistic effect%immune function
目的：研究蛋氨酸脑啡肽（MEK）是否具有抗癌、增加化疗药物疗效和增强或保护免疫功能的作用。方法BALB／c小鼠40只，右腋皮下接种H22癌细胞，接种24 h后随机分为5组，依次为阴性对照组（生理盐水0.2 mL／kg）、5‐Fu组（10 mg／kg）、MEK组（200 mg／kg）、5‐Fu＋MEK联合给药组（10 mg／kg＋200 mg／kg）和阳性对照组（20 mg／kg 5‐Fu）。腹腔注射受试药品，每日1次，连续给药8 d ，处死动物。计算肿瘤抑制率、胸腺和脾脏脏器指数以及测定CD3＋和CD4＋ T细胞表达。结果单独给予MEK 200 mg／kg或5‐Fu 10 mg／kg时两组对肿瘤的抑制作用相近，对肿瘤的抑制率分别为75.13％和74.26％；联合给予MEK和5‐Fu时，其抑瘤率为88.25％，明显高于单独使用5‐Fu。MEK对小鼠脾脏及胸腺无明显抑制作用，与5‐Fu合用时能显著减轻5‐Fu对免疫脏器胸腺的抑制作用。单独给予MEK 200 mg／kg时，能明显提高荷瘤小鼠的CD3＋和CD4＋ T细胞表达，与阴性对照组和5‐Fu各剂量组比较差异均有统计学意义（均 P＜0.05）。结论 MEK具有良好的抗肿瘤活性及增强机体免疫功能的作用，与化疗药物合用能增强其疗效同时减轻其毒性，对免疫脏器有保护作用。
目的：研究蛋氨痠腦啡肽（MEK）是否具有抗癌、增加化療藥物療效和增彊或保護免疫功能的作用。方法BALB／c小鼠40隻，右腋皮下接種H22癌細胞，接種24 h後隨機分為5組，依次為陰性對照組（生理鹽水0.2 mL／kg）、5‐Fu組（10 mg／kg）、MEK組（200 mg／kg）、5‐Fu＋MEK聯閤給藥組（10 mg／kg＋200 mg／kg）和暘性對照組（20 mg／kg 5‐Fu）。腹腔註射受試藥品，每日1次，連續給藥8 d ，處死動物。計算腫瘤抑製率、胸腺和脾髒髒器指數以及測定CD3＋和CD4＋ T細胞錶達。結果單獨給予MEK 200 mg／kg或5‐Fu 10 mg／kg時兩組對腫瘤的抑製作用相近，對腫瘤的抑製率分彆為75.13％和74.26％；聯閤給予MEK和5‐Fu時，其抑瘤率為88.25％，明顯高于單獨使用5‐Fu。MEK對小鼠脾髒及胸腺無明顯抑製作用，與5‐Fu閤用時能顯著減輕5‐Fu對免疫髒器胸腺的抑製作用。單獨給予MEK 200 mg／kg時，能明顯提高荷瘤小鼠的CD3＋和CD4＋ T細胞錶達，與陰性對照組和5‐Fu各劑量組比較差異均有統計學意義（均 P＜0.05）。結論 MEK具有良好的抗腫瘤活性及增彊機體免疫功能的作用，與化療藥物閤用能增彊其療效同時減輕其毒性，對免疫髒器有保護作用。
목적：연구단안산뇌배태（MEK）시부구유항암、증가화료약물료효화증강혹보호면역공능적작용。방법BALB／c소서40지，우액피하접충H22암세포，접충24 h후수궤분위5조，의차위음성대조조（생리염수0.2 mL／kg）、5‐Fu조（10 mg／kg）、MEK조（200 mg／kg）、5‐Fu＋MEK연합급약조（10 mg／kg＋200 mg／kg）화양성대조조（20 mg／kg 5‐Fu）。복강주사수시약품，매일1차，련속급약8 d ，처사동물。계산종류억제솔、흉선화비장장기지수이급측정CD3＋화CD4＋ T세포표체。결과단독급여MEK 200 mg／kg혹5‐Fu 10 mg／kg시량조대종류적억제작용상근，대종류적억제솔분별위75.13％화74.26％；연합급여MEK화5‐Fu시，기억류솔위88.25％，명현고우단독사용5‐Fu。MEK대소서비장급흉선무명현억제작용，여5‐Fu합용시능현저감경5‐Fu대면역장기흉선적억제작용。단독급여MEK 200 mg／kg시，능명현제고하류소서적CD3＋화CD4＋ T세포표체，여음성대조조화5‐Fu각제량조비교차이균유통계학의의（균 P＜0.05）。결론 MEK구유량호적항종류활성급증강궤체면역공능적작용，여화료약물합용능증강기료효동시감경기독성，대면역장기유보호작용。
Objective To study the anti‐tumor ,chemotherapy‐sensitizing and immune‐enhancing roles of methionine‐en‐kephalin(MEK).Methods Experimental BALB/c mice were subcutaneously inoculated with H22 tumor cells in right axillary regions.They were divided into 5 groups at random :negative control group(0.2 mL/kg NaCl) ,5‐Fu group(10 mg/kg 5‐Fu) , MEK group(200 mg/kg MEK) ,5‐Fu+MEK group(10 mg/kg 5‐Fu+200 mg/kg MEK)and positive control group(20 mg/kg 5‐Fu).Animals in each group were intraperitoneally injected with agents once a day for 8 days after inoculated with tumor cells 24 h later.The anti‐tumor rate ,organ indexes of the thymus and spleen and the proportion of CD3+ /CD4+ were calculat‐ed.Results The anti‐tumor rate was 75.13% in MEK group and 74.26% in 5‐Fu group and there was no significant differ‐ence.It was 88.25% in 5‐Fu+ MEK group ,significantly higher than in 5‐Fu group.MEK had no significant inhibition on the spleen and thymus.The inhibitive effect of 5‐Fu on the thymus and spleen was significantly attenuated after administration with MEK.Moreover ,MEK could enhance the proportion of CD3+ and CD4+ significantly(P<0.05) ,and statistical difference was noted between MEK group and control or 5‐Fu group.Conclusion MEK has remarkable anti‐tumor activity and it can booster immune functions ,enhance the efficacy of chemotherapeutics while reducing their toxicity when co‐administered.Meantime ,it could protect the immune organs.
